INTRODUCTION AND OBJECTIVES: Multivariable risk calculators (RC) predicting prostate cancer (PCa) aim to reduce unnecessary biopsies and improve detection of clinically significant PCa (Gleason 7). We aimed to evaluate well-known RCs in a head-to-head comparison.
METHODS: Our multicentre study comprised 7158 men from 10 independent contemporary cohorts in Europe and Australia who underwent prostate biopsy in 2007-2015. We evaluated the performance of the ERSPC, Finne, Chun, ProstataClass, Karakiewicz, Sunnybrook, and PCPT(HG) RCs in predicting the presence of any PCa and clinically significant PCa.
RESULTS: A total of 3509 (49%) PCa were detected; 1866 (26%) men had clinically significant PCa. In predicting any PCa no particular RC stood out, pooled area under the ROC-curve (AUC) ranged between 0.66 and 0.73 ( Fig. 1 ). Substantial heterogeneity in the AUC was found between the cohorts (range I 2 74%-94%). The ERSPC RC had the highest pooled AUC 0.77 (95% CI: 0.73-0.81) in predicting clinically significant PCa, and was statistically significantly better than the other RCs.
CONCLUSIONS: No particular risk calculator stands out to discriminate between men with and without PCa across a range of settings, but the ERSPC is most promising to identify those with clinically significant PCa. Further research is necessary to evaluate the practical usefulness and clinical impact of these RCs. , was developed to include information on prostate volume but to circumvent the need for imaging studies, enabling easier implementation into daily practice of urologists and general practitioners (GPs). Our objective was to assess the level of agreement between DRE findings (irregularities and estimation of volume) of two urologists in men suspicious for PCa and, subsequently, the potential effect on risk prediction using the DRE-based RPCRC.
Source of Funding: None
METHODS: A prospective cohort of asymptomatic and unscreened men with PSA <¼50.0 ng/mL and TRUS (transrectal ultrasonography) volume <¼110 mL who underwent 16-core TRUS-guided Bx were evaluated. Both urologists' DRE findings were graded normal or abnormal (i.e. nodularity and/or induration), and volume classified as 25mL, 40mL or 60mL, according to the RPCRC algorithm. Inter-rater agreement analysis using Cohens's kappa (?) statistic was performed to determine consistency of DRE outcome and volume assessment. Receiver operating characteristic (ROC) curve analysis and calibration plots were constructed per urologist to determine the effect of inter-rater differences. Decision curve analysis (DCA) was applied to evaluate the clinical usefulness of the DRE based model. RESULTS: Of the 241 men included in the study, 41% (n ¼ 98) had a positive Bx (81 PCa were clinically significant). There was substantial agreement in the DRE examination (abnormal/normal) (? ¼ 0.78; P < 0.001), and volume estimation (? ¼ 0.79; P < 0.001). ROC analyses showed good discrimination (0.75e0.78) and were highly comparable for both urologists. In our high risk cohort, at a probability threshold of 25%, the DRE-based RPCRC reduces the Bx rate by 9%, without missing cancers.
CONCLUSIONS: This is the first study to validate the DREversion of the RPCRC. Most crucial in this validation is the effect of the e1026 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
